Australian Broker Call
Produced and copyrighted by at www.fnarena.com
September 06, 2023
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1).
Last Updated: 05:00 PM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
Today's Upgrades and Downgrades
COH - | Cochlear | Downgrade to Underweight from Equal-weight | Morgan Stanley |
HVN - | Harvey Norman | Downgrade to Underweight from Equal-weight | Morgan Stanley |
RMD - | ResMed | Downgrade to Neutral from Buy | UBS |
Ord Minnett rates ABG as Buy (1) -
Having reviewed Abacus Group following the separation of Abacus Strorage King, Ord Minnett notes the retail portfolio is trading well, while the office portfolio faces new supply and soft demand.
The shares screen significantly undervalued, in the broker's view, although rising interest costs are likely to "roughly offset" revenue growth for the next three years.
While the older buildings in the portfolio are not well-positioned for the new hybrid working arrangements, Ord Minnett suspects rental downside is limited.
Two thirds of the commercial portfolio are from 15 offices while the other third is retail and other properties. Buy rating retained. Target is reduced to $1.75 from $1.90.
Target price is $1.75 Current Price is $1.15 Difference: $0.605
If ABG meets the Ord Minnett target it will return approximately 53% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Ord Minnett forecasts a full year FY24 dividend of 8.50 cents and EPS of 7.60 cents. |
Forecast for FY25:
Ord Minnett forecasts a full year FY25 dividend of 8.20 cents and EPS of 7.60 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.28
Bell Potter rates BCI as Speculative Buy (1) -
Bell Potter incorporates the new details for the Mardie salt and potash project. BCI Minerals has highlighted base capital costs are up 57% on the 2021 FID and first salt production will now be in the second half of 2026 compared with prior estimates of 2024.
As of June 30 the construction was around 25% complete with -$369m spent. Conditional credit approval from lenders for up to $800m in undrawn debt finance has been received and other conditional debt facilities are being negotiated.
Bell Potter now makes a Speculative addition to its Buy rating to account for the gap between Iron Valley earnings and the delayed ramp up of the Mardie project. Target is raised to $0.44 from $0.32.
Target price is $0.44 Current Price is $0.28 Difference: $0.155
If BCI meets the Bell Potter target it will return approximately 54% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.50 cents. |
Forecast for FY25:
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.36
Morgan Stanley rates BTH as Overweight (1) -
After a softer-than-expected FY23 result from Bigtincan Holdings, which was largely pre-guided, Morgan Stanley re-bases revenue and lowers operating expenditure assumptions.
The broker envisages lingering uncertainty despite the improved free cash flow and lowers earnings estimates to reflect a softer topline. Overweight. Target is reduced to $0.73 from $0.95. Industry view: In line.
Target price is $0.73 Current Price is $0.36 Difference: $0.375
If BTH meets the Morgan Stanley target it will return approximately 106% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 1.00 cents. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CMW CROMWELL PROPERTY GROUP
Infra & Property Developers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $0.47
Morgans rates CMW as Hold (3) -
Cromwell Property's FY23 operating profit of 6.06cps compared to Morgans forecast for 6.3cps due to lower contributions from funds management (no retail transactional fees) and impacts from asset sales.
Additionally, profits suffered from lower co-investment income and materially higher interest costs, explains the broker.
Gearing remains elevated, so management's focus remains on debt reduction via asset sales, points out Morgans.
While there was no formal FY24 guidance, management forecast a distribution of 0.83cpu will be paid for the September quarter, which if annualised, equates to 3.32cpu, down from 5.5cpu in FY23, explains the broker.
Target price is $0.70 Current Price is $0.47 Difference: $0.235
If CMW meets the Morgans target it will return approximately 51% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY24:
Morgans forecasts a full year FY24 dividend of 3.30 cents and EPS of 5.10 cents. |
Forecast for FY25:
Morgans forecasts a full year FY25 dividend of 3.40 cents and EPS of 5.20 cents. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $270.12
Morgan Stanley rates COH as Downgrade to Underweight from Equal-weight (5) -
Since the FY23 result Cochlear has rallied around 16%, outperforming the S&P/ASX200 industrials. As the stock is now trading "well north" of Morgan Stanley's price target of $240 and at a premium to its historical forward PE average, the rating is downgraded to Underweight from Equal-weight.
The company has guided to slowing unit growth into FY24 and the upgrades from the installed base are now captured in forecasts so the broker assesses there is limited upside surprise potential. Industry view: In-line.
Target price is $240.00 Current Price is $270.12 Difference: minus $30.12 (current price is over target).
If COH meets the Morgan Stanley target it will return approximately minus 11% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $235.73, suggesting downside of -11.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 392.50 cents and EPS of 557.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 551.3, implying annual growth of 20.6%. Current consensus DPS estimate is 386.8, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 48.4. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 429.60 cents and EPS of 609.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 622.1, implying annual growth of 12.8%. Current consensus DPS estimate is 436.1, implying a prospective dividend yield of 1.6%. Current consensus EPS estimate suggests the PER is 42.9. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $6.43
Shaw and Partners rates ELD as Buy (1) -
ABARES has reported the national winter crop will fall to slightly below the 10-year average, to 45.22mt and dry conditions in northern regions are likely to result in below-average yields.
Elders has recently downgraded its earnings guidance for FY23 and now expects underlying EBIT in the range of $165-175m.
While soft commodity prices have been largely stable, livestock prices have fallen further -10% since the company last updated, Shaw and Partners notes.
The broker points out conditions are challenging and Elders is now the fourth most shorted stock on ASX. Buy rating retained. Target is $9.
Target price is $9.00 Current Price is $6.43 Difference: $2.57
If ELD meets the Shaw and Partners target it will return approximately 40% (excluding dividends, fees and charges).
Current consensus price target is $7.25, suggesting upside of 13.6% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY23:
Shaw and Partners forecasts a full year FY23 dividend of 43.00 cents and EPS of 67.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 64.5, implying annual growth of -38.0%. Current consensus DPS estimate is 40.5, implying a prospective dividend yield of 6.3%. Current consensus EPS estimate suggests the PER is 9.9. |
Forecast for FY24:
Shaw and Partners forecasts a full year FY24 dividend of 43.00 cents and EPS of 68.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.6, implying annual growth of -4.5%. Current consensus DPS estimate is 33.1, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 10.4. |
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EOS ELECTRO OPTIC SYSTEMS HOLDINGS LIMITED
Hardware & Equipment
More Research Tools In Stock Analysis - click HERE
Overnight Price: $0.93
Bell Potter rates EOS as Initiation of coverage with Speculative Buy (1) -
Bell Potter initiates coverage of Electro Optic Systems with a Speculative Buy rating and $1.25 target.
Following difficulties experienced in 2022, the broker comments a new management team is in the process of implementing a strategic turnaround, focused on cost discipline and "responsible" growth.
The company has been restructured around its core business lines and achieved -$25m in annualised cost savings, ceasing investment in the SpaceLink program.
The broker notes recent material contracts in both defence and space systems have provided significant visibility on revenue throughout 2023 and 2024.
Target price is $1.25 Current Price is $0.93 Difference: $0.325
If EOS meets the Bell Potter target it will return approximately 35% (excluding dividends, fees and charges).
The company's fiscal year ends in December.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus 39.00 cents. |
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus 20.30 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
Medical Equipment & Devices
More Research Tools In Stock Analysis - click HERE
Overnight Price: $20.77
Morgan Stanley rates FPH as Equal-weight (3) -
Subsequent to Fisher & Paykel Healthcare's trading update on August 28, Morgan Stanley lowers earnings estimates by -3% for FY24 and by -2% for FY25 and thus lowers the target to $21.50 from $22.43. Equal-weight rating. Industry view: In-line.
Target price is $21.50 Current Price is $20.77 Difference: $0.73
If FPH meets the Morgan Stanley target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $21.00, suggesting upside of 3.3% (ex-dividends)
The company's fiscal year ends in March.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 26.86 cents and EPS of 37.72 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 39.9, implying annual growth of N/A. Current consensus DPS estimate is 34.7, implying a prospective dividend yield of 1.7%. Current consensus EPS estimate suggests the PER is 51.0. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 29.53 cents and EPS of 48.75 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 50.5, implying annual growth of 26.6%. Current consensus DPS estimate is 37.2, implying a prospective dividend yield of 1.8%. Current consensus EPS estimate suggests the PER is 40.3. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $7.45
Bell Potter rates GNC as Buy (1) -
The ABARES east coast winter crop forecast is now raised to 20.8mt and the summer crop estimate broadly unchanged at 4.1mt.
Bell Potter continues to suspect the outcome will be softer than the forecaster estimates and suspects marketing returns are unlikely to be at the levels comparable to FY22-23.
The net impact is an upgrade to net profit estimates for Graincorp of 2% in FY24 and 6% in FY25. Buy rating and $9.45 target unchanged.
Target price is $9.45 Current Price is $7.45 Difference: $2
If GNC meets the Bell Potter target it will return approximately 27% (excluding dividends, fees and charges).
Current consensus price target is $8.83, suggesting upside of 21.1% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY23:
Bell Potter forecasts a full year FY23 dividend of 41.00 cents and EPS of 114.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 112.3, implying annual growth of -33.0%. Current consensus DPS estimate is 47.6, implying a prospective dividend yield of 6.5%. Current consensus EPS estimate suggests the PER is 6.5. |
Forecast for FY24:
Bell Potter forecasts a full year FY24 dividend of 22.00 cents and EPS of 49.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 52.3, implying annual growth of -53.4%. Current consensus DPS estimate is 31.6, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 13.9. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates GNC as Hold (3) -
ABARES has marginally increased its 2023/24 winter crop forecast from the June estimate, which will ultimately positively impact on GrainCorp's FY24 earnings. Beyond the current forecast, ABARES flagged clear downside risks given the BOM’s dry weather outlook.
The broker points out GrainCorp will also benefit in the near-term from above average carry over grain of around 3.75mt from FY23, helping to elevate exports.
The broker's target falls to $7.85 from $8.65 after leaving its FY23 earnings (EBITDA) forecast unchanged and lowering the FY24 forecast by -9.8%. The Hold rating is unchanged.
The lower FY24 forecast is due to a crop production payment of -$22m, more conservative grain marketing earnings and lower crush margin assumptions, explain the analysts.
Target price is $7.85 Current Price is $7.45 Difference: $0.4
If GNC meets the Morgans target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $8.83, suggesting upside of 21.1% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY23:
Morgans forecasts a full year FY23 dividend of 54.00 cents and EPS of 115.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 112.3, implying annual growth of -33.0%. Current consensus DPS estimate is 47.6, implying a prospective dividend yield of 6.5%. Current consensus EPS estimate suggests the PER is 6.5. |
Forecast for FY24:
Morgans forecasts a full year FY24 dividend of 35.20 cents and EPS of 50.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 52.3, implying annual growth of -53.4%. Current consensus DPS estimate is 31.6, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 13.9. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HVN HARVEY NORMAN HOLDINGS LIMITED
Furniture & Renovation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.05
Morgan Stanley rates HVN as Downgrade to Underweight from Equal-weight (5) -
Morgan Stanley reviews the divergent trends in the consumer sector, revealed by the reporting season. July trading updates highlight a slowdown in demand although the slowdown was in most cases less than expected and consumer resilience has surprised the broker.
The broker's overweight ratings are skewed to those retailers where growth is driven by offshore expansion or where there is strategic value. As a result, Harvey Norman is downgraded to Underweight from Equal-weight.
The downgrade is premised on exposure to big-ticket items and housing-related expenditure and franchisee margins being historically more volatile through economic cycles. Target is unchanged at $3.50. Industry view is In-Line.
Target price is $3.50 Current Price is $4.05 Difference: minus $0.55 (current price is over target).
If HVN meets the Morgan Stanley target it will return approximately minus 14% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.95, suggesting downside of -1.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 22.00 cents and EPS of 29.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 30.8, implying annual growth of -28.9%. Current consensus DPS estimate is 23.0, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 13.0. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 23.00 cents and EPS of 31.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 34.4, implying annual growth of 11.7%. Current consensus DPS estimate is 25.5, implying a prospective dividend yield of 6.4%. Current consensus EPS estimate suggests the PER is 11.7. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
LAU LINDSAY AUSTRALIA LIMITED
Transportation & Logistics
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.13
Shaw and Partners rates LAU as Buy (1) -
Shaw and Partners transfers coverage to another analyst, observing Lindsay Australia is positioned for long-term profitable growth in a large and attractive target market. Debt is modest, the company pays a dividend and management expertise is high.
The broker updates forecasts to include the FY23 financial results and the acquisition of WB Hunter. FY24 revenue growth of 25.8% is expected along with underlying net profit growth of 16.4%.
Valuation is considered attractive and a Buy rating and $1.60 target are maintained.
Target price is $1.60 Current Price is $1.13 Difference: $0.475
If LAU meets the Shaw and Partners target it will return approximately 42% (excluding dividends, fees and charges).
Current consensus price target is $1.55, suggesting upside of 40.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Shaw and Partners forecasts a full year FY24 dividend of 5.50 cents and EPS of 13.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.8, implying annual growth of 21.1%. Current consensus DPS estimate is 5.9, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 8.0. |
Forecast for FY25:
Shaw and Partners forecasts a full year FY25 dividend of 6.10 cents and EPS of 15.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.0, implying annual growth of 8.7%. Current consensus DPS estimate is 6.3, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 7.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.52
Morgan Stanley rates ORA as Equal-weight (3) -
Orora will acquire Saverglass for -$2.16bn. Mid single-digit accretion is expected within the first year, although Morgan Stanley notes this includes benefits from AASB 133 accounting and its analysis shows a more modest level of accretion after synergies.
Saverglass manufactures high-end bottles for premium and ultra-premium spirits and wine markets with a manufacturing footprint in Europe, Mexico and the UAE.
The transaction will be funded through an equity raising of $1.35bn and $875m in debt. The broker believes the deal is fair but notes this adds a third standalone asset rather than a complementary business. Target is $4 and an Equal-weight rating is maintained. Industry view: In-line.
Target price is $4.00 Current Price is $3.52 Difference: $0.48
If ORA meets the Morgan Stanley target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $3.89, suggesting upside of 34.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 17.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.3, implying annual growth of 6.3%. Current consensus DPS estimate is 17.8, implying a prospective dividend yield of 6.2%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.7, implying annual growth of 6.0%. Current consensus DPS estimate is 19.1, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 11.7. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates ORA as Neutral (3) -
Orora will acquire Saverglass, a global manufacturer of high-end bottles, in a transaction valued at around -$2.2bn. UBS expects investors will be focused on the potential for Saverglass to add earnings growth to the existing Australasian beverage business and the North American distribution platform.
The broker's analysis indicates that around 10% EBITDA growth is required in both FY24 and FY25 to support the delivery of EPS accretion in FY25, given the dilution that will come from the $1.3bn in equity being raised to fund the transaction. Neutral retained. Target is $3.75.
Target price is $3.75 Current Price is $3.52 Difference: $0.23
If ORA meets the UBS target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $3.89, suggesting upside of 34.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
UBS forecasts a full year FY24 dividend of 18.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.3, implying annual growth of 6.3%. Current consensus DPS estimate is 17.8, implying a prospective dividend yield of 6.2%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY25:
UBS forecasts a full year FY25 dividend of 19.00 cents and EPS of 24.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.7, implying annual growth of 6.0%. Current consensus DPS estimate is 19.1, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 11.7. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PNV POLYNOVO LIMITED
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.35
Morgans rates PNV as Initiation of coverage with Add (1) -
Morgans initiates coverage on medical device company PolyNovo with an Add rating and $1.88 target. It's felt clinical trials will support expanded indications and entry into new geographies, resulting in yearly revenue growth of around 30% over the next three years.
The broker predicts breakeven for PolyNovo will be achieved in FY24, followed by profit growth from FY25 onward. The company specialises in the development and commercialisation of dermal regenerative solutions.
Approved products are NovoSorb BTM and NovoSorb MTX, which are synthetic polymer-based scaffolds designed to be used in the treatment of burns and surgical wounds, explain the analysts.
Target price is $1.88 Current Price is $1.35 Difference: $0.53
If PNV meets the Morgans target it will return approximately 39% (excluding dividends, fees and charges).
Current consensus price target is $2.19, suggesting upside of 64.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 0.1, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 1330.0. |
Forecast for FY25:
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 1.4, implying annual growth of 1300.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 95.0. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
QAN QANTAS AIRWAYS LIMITED
Travel, Leisure & Tourism
More Research Tools In Stock Analysis - click HERE
Overnight Price: $5.64
Morgan Stanley rates QAN as Overweight (1) -
Morgan Stanley finds the announcement that CEO Alan Joyce will step down two months early "something of a surprise". No meaningful valuation or share price implications are taken, given the succession to Vanessa Hudson has been flagged for some time.
The news follows recent ACCC proceedings along with a "number of negative press reports" and it may provide a circuit breaker, the broker suggests, limiting brand damage. Overweight rating and $9 target maintained. Industrry view is In-Line.
Target price is $9.00 Current Price is $5.64 Difference: $3.36
If QAN meets the Morgan Stanley target it will return approximately 60% (excluding dividends, fees and charges).
Current consensus price target is $7.78, suggesting upside of 36.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 0.00 cents and EPS of 117.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 107.4, implying annual growth of 11.8%. Current consensus DPS estimate is 1.7, implying a prospective dividend yield of 0.3%. Current consensus EPS estimate suggests the PER is 5.3. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 26.00 cents and EPS of 123.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 110.2, implying annual growth of 2.6%. Current consensus DPS estimate is 25.8, implying a prospective dividend yield of 4.5%. Current consensus EPS estimate suggests the PER is 5.2. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $24.52
Morgan Stanley rates RMD as Equal-weight (3) -
Since the FY23 result Morgan Stanley updates its sensitivity analysis in relation to anti-obesity medications, and as a result the associated element in its ResMed bear case.
Accounting for all the changes in its calculations, the broker lowers the target to $27.70 from $31.40. Equal-weight retained. Industry View: In-Line.
Target price is $27.70 Current Price is $24.52 Difference: $3.18
If RMD meets the Morgan Stanley target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $35.83, suggesting upside of 50.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 28.81 cents and EPS of 104.66 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 114.0, implying annual growth of N/A. Current consensus DPS estimate is 30.7, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 20.9. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 28.81 cents and EPS of 113.96 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.3, implying annual growth of 12.5%. Current consensus DPS estimate is 33.9, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 18.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates RMD as Downgrade to Neutral from Buy (3) -
Having previously argued the market was probably running ahead of reality by selling off ResMed shares on the basis of the ever growing popularity of the latest generation of ant-obesity drugs, FNArena believes ResMed shares have been downgraded to Neutral from Buy by UBS.
The broker now believes the competitive threat from these drugs on the sleep apnoea market stands ready to create an estimated -14% volume headwind for the company's sleep business by 2030.
There still is a wide dispersion in potential outcomes, the analysts argue, adding any impact won't be felt until many years into the future. UBS's forecasts drop significantly after 2030.
The target price has fallen to US$170 from US$265.
Current Price is $24.52. Target price not assessed.
Current consensus price target is $35.83, suggesting upside of 50.3% (ex-dividends)
Forecast for FY24:
Current consensus EPS estimate is 114.0, implying annual growth of N/A. Current consensus DPS estimate is 30.7, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 20.9. |
Forecast for FY25:
Current consensus EPS estimate is 128.3, implying annual growth of 12.5%. Current consensus DPS estimate is 33.9, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 18.6. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $32.39
Morgan Stanley rates SHL as Overweight (1) -
Morgan Stanley again revises assumptions for Sonic Healthcare in the wake of the FY23 results. A longer-term margin contribution is anticipated from faster growth in specialist testing. The broker also reviews the cost of debt.
Target is raised to $36.60 from $34.80 as a result. Overweight. Industry view is In-Line.
Target price is $36.60 Current Price is $32.39 Difference: $4.21
If SHL meets the Morgan Stanley target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $35.61, suggesting upside of 13.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY24:
Morgan Stanley forecasts a full year FY24 dividend of 106.80 cents and EPS of 135.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.4, implying annual growth of -2.3%. Current consensus DPS estimate is 107.3, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 22.1. |
Forecast for FY25:
Morgan Stanley forecasts a full year FY25 dividend of 109.20 cents and EPS of 149.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 157.3, implying annual growth of 10.5%. Current consensus DPS estimate is 111.9, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 20.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.21
Morgans rates TNC as Speculative Buy (1) -
Morgans begins research coverage with a Speculative Buy rating on True North Copper, an emerging copper producer from the Cloncurry District in northwest Queensland.
In the broker's opinion, the current market capitalisation is far too cheap by comparison to peers and after taking into account potential free cash flows of $40-50m per annum by FY25. It's felt quick cash generation via an efficient ramp-up will be a key re-rating catalyst.
The analyst explains immediate production from the Cloncurry Project should allow self-funded exploration across an extensive portfolio of known copper deposits.
Morgans sets a 45c target price.
Target price is $0.45 Current Price is $0.21 Difference: $0.245
If TNC meets the Morgans target it will return approximately 120% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Today's Price Target Changes
Company | Last Price | Broker | New Target | Prev Target | Change | |
ABG | Abacus Group | $1.13 | Ord Minnett | 1.75 | 1.90 | -7.89% |
BCI | BCI Minerals | $0.28 | Bell Potter | 0.44 | 0.32 | 37.50% |
BTH | Bigtincan Holdings | $0.36 | Morgan Stanley | 0.73 | 0.95 | -23.16% |
CMW | Cromwell Property | $0.45 | Morgans | 0.70 | 0.88 | -20.45% |
FPH | Fisher & Paykel Healthcare | $20.33 | Morgan Stanley | 21.50 | N/A | - |
GNC | GrainCorp | $7.29 | Morgans | 7.85 | 8.65 | -9.25% |
ORA | Orora | $2.89 | Morgan Stanley | 4.00 | 3.70 | 8.11% |
RMD | ResMed | $23.84 | Morgan Stanley | 27.70 | 31.40 | -11.78% |
SHL | Sonic Healthcare | $31.43 | Morgan Stanley | 36.60 | 34.80 | 5.17% |
Summaries
ABG | Abacus Group | Buy - Ord Minnett | Overnight Price $1.15 |
BCI | BCI Minerals | Speculative Buy - Bell Potter | Overnight Price $0.28 |
BTH | Bigtincan Holdings | Overweight - Morgan Stanley | Overnight Price $0.36 |
CMW | Cromwell Property | Hold - Morgans | Overnight Price $0.47 |
COH | Cochlear | Downgrade to Underweight from Equal-weight - Morgan Stanley | Overnight Price $270.12 |
ELD | Elders | Buy - Shaw and Partners | Overnight Price $6.43 |
EOS | Electro Optic Systems | Initiation of coverage with Speculative Buy - Bell Potter | Overnight Price $0.93 |
FPH | Fisher & Paykel Healthcare | Equal-weight - Morgan Stanley | Overnight Price $20.77 |
GNC | GrainCorp | Buy - Bell Potter | Overnight Price $7.45 |
Hold - Morgans | Overnight Price $7.45 | ||
HVN | Harvey Norman | Downgrade to Underweight from Equal-weight - Morgan Stanley | Overnight Price $4.05 |
LAU | Lindsay Australia | Buy - Shaw and Partners | Overnight Price $1.13 |
ORA | Orora | Equal-weight - Morgan Stanley | Overnight Price $3.52 |
Neutral - UBS | Overnight Price $3.52 | ||
PNV | PolyNovo | Initiation of coverage with Add - Morgans | Overnight Price $1.35 |
QAN | Qantas Airways | Overweight - Morgan Stanley | Overnight Price $5.64 |
RMD | ResMed | Equal-weight - Morgan Stanley | Overnight Price $24.52 |
Downgrade to Neutral from Buy - UBS | Overnight Price $24.52 | ||
SHL | Sonic Healthcare | Overweight - Morgan Stanley | Overnight Price $32.39 |
TNC | True North Copper | Speculative Buy - Morgans | Overnight Price $0.21 |
RATING SUMMARY
Rating | No. Of Recommendations |
1. Buy | 11 |
3. Hold | 7 |
5. Sell | 2 |
Wednesday 06 September 2023
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
1 |
Monthly Listed Investment Trust Report – Oct 202412:00 PM - Australia |
2 |
The Case For Charter Hall11:30 AM - Australia |
3 |
Australian Listed Real Estate Tables – 07-10-202411:00 AM - Weekly Reports |
4 |
Australian Banks: When The End Of The Trend?10:38 AM - Feature Stories |
5 |
Weekly Ratings, Targets, Forecast Changes – 04-10-2410:00 AM - Weekly Reports |